Highmark denied your Zepbound. Here is how to appeal it.

Why Highmark denies Zepbound

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity (BMI 30 or higher), or with excess weight (BMI 27 or higher) plus a weight-related condition, and separately for moderate-to-severe obstructive sleep apnea in adults with obesity. Highmark can cover it under the pharmacy benefit, but it usually sits behind prior authorization and, on many plans, step therapy. Denials tend to follow a few patterns:

• Not medically necessary. Highmark frequently applies a blanket 'not medically necessary' designation. A denial often means the submitted records did not, in Highmark's reading, meet the criteria in its medical policy, even when the prescription is appropriate.
• Retrospective reversal after pre-authorization. Highmark has documented authority to reverse a treatment it pre-authorized when it reviews the claim after the fact. If that happened, the timing and the original authorization are both worth raising.
• Plan exclusion for weight-loss drugs. Some employer plans carve out anti-obesity medications entirely. This is the hardest kind to overturn, but it is worth confirming the exclusion actually applies to your specific plan and your diagnosis before accepting it.
• The sleep apnea path is often missed. If you have moderate-to-severe obstructive sleep apnea with obesity, that is a separate FDA-approved indication for Zepbound. A denial framed only around weight loss may not have considered this second covered route.

How to win the appeal with Highmark

The pattern that works against Highmark is to use the peer-to-peer review first, and to hold Highmark to its own reviewer-specialty rule.

• Start with a peer-to-peer. Ask your prescriber to request a P2P review with Highmark's medical director before any formal appeal. Highmark reverses a large share of denials at this stage.
• Name the medical policy in writing and answer each criterion in order, with the page of your record that proves it.
• Attach the documentation the policy asks for: BMI history, the weight-related conditions, and any prior weight-management efforts, dated.
• If you have obstructive sleep apnea, attach the diagnosis and sleep-study evidence and ask the plan to review Zepbound under that FDA-approved indication.
• File within the window. Highmark commercial plans in DE, NY, PA, and WV give you 180 days from the initial denial. If your internal appeal is upheld, you have the right to an external review by an Independent Review Organization.
• Demand a same-specialty reviewer. Highmark's own rules require the clinical peer reviewer to be board-certified in the same or a similar specialty that typically manages your condition. If that did not happen, say so in writing, it is grounds to challenge the denial.

Sources include Highmark's published medical policies and the Zepbound prescribing information. We cite the specific policy that applies to your plan when we build your appeal.

Highmark + Zepbound: common questions

Other Zepbound appeals: Florida Blue · Independence Blue Cross · Aetna · All Zepbound denials